产品
编 号：F486602
分子式：C14H17IN4O2
分子量：400.21
分子式：C14H17IN4O2
分子量：400.21
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 865305-30-2
产品详情
生物活性：
AF-353 (Ro-4) is a potent, selective and orally bioavailable P2X3/P2X2/3 receptor antagonist, with a pIC50 of 8.0 for both human and rat P2X3, and with a pIC50 of 7.3 for human P2X2/3.
体内研究：
AF-353 (Ro-4) does not compromise oxygen levels or cardiac function.AF-353 (Ro-4) (10 mg/kg, 20 mg/kg; i.v.; for 4-6 hours) inhibits the purinergic response in both normal and spinal cord-injured (SCI) rats.AF-353 (Ro-4) (10 mg/kg, 20 mg/kg; i.v.; for 4-6 hours) also reduces the inter-contractile interval in normal but not in SCI rats; however, the frequency of non-voiding (NVC) in SCI rats is significantly reduced.Animal Model:Female Sprague-Dawley rats (250–300 g) bearing SCI
Dosage:10 mg/kg, 20 mg/kg
Administration:Intravenous injection; interval of 90 minutes, for 4 hours to 6 hours
Result:Significantly reduced purinergic response in both normal and SCI rats.
体外研究：
AF-353 (Ro-4) is a highly potent inhibitor of α,β-meATP-evoked intracellular calcium flux in cell lines expressing recombinant rat and human P2X3 and human P2X2/3 channels.AF-353 (Ro-4) also blocks human P2X2/3 channel function with marginally reduced potency with a p50 of 7.3.
AF-353 (Ro-4) is a potent, selective and orally bioavailable P2X3/P2X2/3 receptor antagonist, with a pIC50 of 8.0 for both human and rat P2X3, and with a pIC50 of 7.3 for human P2X2/3.
体内研究：
AF-353 (Ro-4) does not compromise oxygen levels or cardiac function.AF-353 (Ro-4) (10 mg/kg, 20 mg/kg; i.v.; for 4-6 hours) inhibits the purinergic response in both normal and spinal cord-injured (SCI) rats.AF-353 (Ro-4) (10 mg/kg, 20 mg/kg; i.v.; for 4-6 hours) also reduces the inter-contractile interval in normal but not in SCI rats; however, the frequency of non-voiding (NVC) in SCI rats is significantly reduced.Animal Model:Female Sprague-Dawley rats (250–300 g) bearing SCI
Dosage:10 mg/kg, 20 mg/kg
Administration:Intravenous injection; interval of 90 minutes, for 4 hours to 6 hours
Result:Significantly reduced purinergic response in both normal and SCI rats.
体外研究：
AF-353 (Ro-4) is a highly potent inhibitor of α,β-meATP-evoked intracellular calcium flux in cell lines expressing recombinant rat and human P2X3 and human P2X2/3 channels.AF-353 (Ro-4) also blocks human P2X2/3 channel function with marginally reduced potency with a p50 of 7.3.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备